Deciphera Pharmaceuticals Inc
NASDAQ:DCPH 9:38:18 AM EDT
| Market Cap (Intraday) | 1.19B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $15.04 |
| 50-Day MA | $15.64 |
| 200-Day MA | $14.05 |
Deciphera Pharmaceuticals Inc Stock, NASDAQ:DCPH
200 Smith Street, 6th floor, Waltham, Massachusetts 02451
United States of America
Phone: +1.781.209.6400
Number of Employees: 355
Description
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.